The World Health Organization says Ebola transmission is declining in some of the hardest-hit areas of the Democratic Republic of the Congo. The improvement is most visible in parts of Ituri province, the main center of the outbreak. However, the epidemic continues to expand in other areas. Official data through Sept. 13 showed 7,258 confirmed cases and 3,510 deaths across seven provinces, with the national case fatality ratio at 48.4%.

The New York Yankees said the current outbreak has not been linked to Yankee Stadium. The team said its cooling towers were installed in 2024 and receive regular water quality checks. A Legionella test performed Aug. 20 returned a negative result. The Yankees also conducted weekly water quality and bacteriological indicator testing on Aug. 26, Sept. 2 and Sept. 9, before city investigators collected the stadium sample on Sept. 11.

The World Health Organization has urged a wider Ebola response in the Democratic Republic of the Congo as transmission continues across several provinces. Congo had recorded 6,250 confirmed cases and 3,039 deaths by Sept. 1, according to the latest government figures. The outbreak has affected 60 health zones in six provinces. Authorities have also recorded 1,439 recoveries, while the case fatality rate stands at 48.6%.

Health Minister Roger Kamba confirmed that the government initiated the immunization campaign utilizing doses of the Ervebo vaccine to safeguard frontline personnel operating across impacted eastern provinces.

The European Commission has expanded its Ebola response with a €2.1 million purchase of PCR tests for the Bundibugyo virus outbreak. The agreement covers open-platform tests that laboratories can use with existing systems. Shipments are due to start in August as health teams confront a large outbreak centered in the Democratic Republic of the Congo and affecting parts of the wider region.

Australian researchers from Adelaide University and the Olivia Newton-John Cancer Research Institute have identified a novel molecular switch that drives the spread of aggressive tumors. Published in EMBO Molecular Medicine, the breakthrough study reveals that Australian researchers uncover a promising new way to tackle triple-negative breast cancer by restoring a critical regulatory molecule known as miR-342. The discovery opens new avenues to prevent life-threatening secondary cancers in organs such as the lungs and bones.